암 면역치료 Drug Discovery 아웃소싱 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 약제 유형별, 서비스 유형별, 암 유형별, 지역별 부문, 경쟁(2020-2030년)

Cancer Immunotherapy Drug Discovery Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Service Type, by Cancer Type, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,511,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,957,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,575,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

암 면역치료 Drug Discovery 아웃소싱 세계 시장 규모는 2024년 12억 9,000만 달러로 평가되었고, 예측기간 동안 8.80%의 연평균 복합 성장률(CAGR)로 2030년에는 21억 4,000만 달러에 달할 것으로 예상됩니다.

암 면역치료제 신약개발 아웃소싱은 제약 및 생명공학 산업에 특화된 서비스 모델입니다. 암 면역치료제 신약개발 프로세스의 다양한 측면을 CRO(Contract Research Organization: 연구개발 업무 위탁기관)나 CDMO(Contract Development and Manufacturing Organization: 개발 제조 업무 위탁기관)로 알려진 외부 서비스 제공업체에 아웃소싱하는 것입니다. 기관)으로 알려진 외부 서비스 제공업체에 아웃소싱하는 것입니다. 이 아웃소싱 모델은 제약사가 외부의 전문 지식, 인프라, 자원을 활용하여 혁신적인 암 면역항암제 개발을 가속화하기 위한 것입니다. 암 면역항암제 개발 과정에는 일반적으로 표적 발굴, 전임상 연구, 임상시험 관리, 의약품 허가 등 여러 단계가 포함됩니다. 아웃소싱은 이러한 단계의 다양한 측면을 커버할 수 있습니다. 아웃소싱을 통해 위험을 공유하는 것은 제약업계에서 흔히 볼 수 있는 전략입니다. 외부 전문가와 협력함으로써 기업은 과학적 위험과 재정적 위험을 줄일 수 있습니다. 면역관문억제제, CAR-T 세포치료제, 단클론항체 등 면역치료 접근법의 급속한 발전과 성공은 이 분야에 대한 큰 관심과 투자를 불러일으켰습니다. 개인 맞춤형 의료로의 전환으로 환자 개개인에 특화된 바이오마커와 유전적 표적의 식별에 초점이 맞추어지고 있습니다. 이에 따라 바이오마커 발굴 및 의약품 개발 아웃소싱 서비스가 요구되고 있습니다. 환자들은 면역치료가 효과적인 암 치료 옵션이라는 것을 인식하게 되었고, 종종 이러한 치료를 요구하고 있습니다. 이러한 환자들 수요 증가는 제약회사들이 면역치료제 개발에 투자하는 원동력이 되고 있습니다. 연구를 통해 암의 유전적, 분자적 기전에 대한 새로운 지식이 발견됨에 따라 희귀암을 포함한 다양한 암종에 대한 면역치료제 개발에 초점을 맞추었습니다. 표적 발굴, 전임상 연구, 임상시험 관리 등 신약 개발의 특정 측면을 아웃소싱함으로써 제약회사는 R&D 비용을 절감하고 자원을 보다 효율적으로 배분할 수 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	12억 9,000만 달러
시장 규모 : 2030년	21억 4,000만 달러
CAGR : 2025-2030년	8.80%
급성장 부문	타겟 식별 및 검증
최대 시장	북미

시장 성장 촉진요인

환자 수요와 인식 증가

시장의 과제

품질 관리 및 표준화

주요 시장 동향

체크포인트 억제제 조사 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 암 면역치료 Drug Discovery 아웃소싱 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 약제 유형별(단일클론항체, 면역조절제, 암백신, 종양용해성 바이러스 요법 등)
  • 서비스 유형별(타겟 특정 및 검증, 리드 스크리닝 및 특성 평가, 세포 기반 어세이)
  • 암 유형별(폐암, 유방암, 대장암, 흑색종, 전립선암, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 암 면역치료 Drug Discovery 아웃소싱 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 암 면역치료 Drug Discovery 아웃소싱 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 암 면역치료 Drug Discovery 아웃소싱 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제9장 남미의 암 면역치료 Drug Discovery 아웃소싱 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 암 면역치료 Drug Discovery 아웃소싱 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 암 면역치료 Drug Discovery 아웃소싱 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Covance, Inc.
• Horizon Discovery Group PLC
• Crown Bioscience, Inc.
• Promega Corporation
• HD Biosciences Co., Ltd.
• BPS Bioscience, Inc.
• Genscript Biotech Corporation
• DiscoverX Corporation
• Celentyx Ltd.
• ImmunXperts SA

제17장 전략적 제안

제18장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Cancer Immunotherapy Drug Discovery Outsourcing Market was valued at USD 1.29 billion in 2024 and is expected to reach USD 2.14 billion by 2030 with a CAGR of 8.80% during the forecast period. Cancer Immunotherapy Drug Discovery Outsourcing is a specialized service model within the pharmaceutical and biotechnology industry. It involves the outsourcing of various aspects of the drug discovery and development process for cancer immunotherapies to external service providers, often known as Contract Research Organizations (CROs) or Contract Development and Manufacturing Organizations (CDMOs). This outsourcing model is designed to accelerate the development of innovative cancer immunotherapies while allowing pharmaceutical companies to leverage external expertise, infrastructure, and resources. The drug discovery process for cancer immunotherapies typically involves several stages, including target identification, preclinical research, clinical trial management, and regulatory approval. Outsourcing can cover various aspects of these stages. Sharing risks with outsourcing partners is a common strategy in the pharmaceutical industry. By partnering with external experts, companies can mitigate scientific and financial risks. The rapid development and success of immunotherapy approaches, such as immune checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, have driven significant interest and investment in the field. The shift toward personalized medicine has led to a focus on identifying specific biomarkers and genetic targets for individual patients. This necessitates outsourcing services for biomarker discovery and drug development. Patients are becoming more aware of immunotherapy as a viable cancer treatment option, and they often seek out these therapies. This increased patient demand drives pharmaceutical companies to invest in immunotherapy drug discovery. As research uncovers new insights into the genetic and molecular mechanisms of cancer, the focus on developing immunotherapies for a broader range of cancer types, including rare cancers, has increased. Outsourcing certain aspects of drug discovery, such as target identification, preclinical research, and clinical trial management, helps pharmaceutical companies reduce research and development costs and allocate resources more efficiently.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.29 Billion
Market Size 2030	USD 2.14 Billion
CAGR 2025-2030	8.80%
Fastest Growing Segment	Target Identification and Validation
Largest Market	North America

Key Market Drivers

Increasing Patient Demand and Awareness

Patients today have greater access to information about cancer treatment options, including immunotherapy, through the internet, social media, and patient advocacy groups. This increased awareness leads patients to seek out the latest and most promising therapies. Many patients with cancer are seeking innovative and more effective treatments, especially when traditional therapies have not yielded satisfactory results or are associated with significant side effects. Immunotherapies represent a promising and less toxic approach. Awareness about the concept of personalized medicine has grown. Patients are increasingly aware that cancer immunotherapies can be tailored to their specific genetic and molecular profiles, making them more effective and less likely to cause adverse effects. Patients are more willing to participate in clinical trials, as they recognize the potential benefits of receiving cutting-edge treatments. Clinical trials often rely on outsourcing services for various aspects, including patient recruitment and data management. Patient advocacy groups and organizations dedicated to specific types of cancer actively promote awareness about the latest treatments, including immunotherapies. They often collaborate with researchers and pharmaceutical companies, indirectly contributing to the growth of outsourcing services. As patients become more informed, they engage in discussions with their healthcare providers about treatment options, including immunotherapy. This dialogue drives interest in these therapies and encourages healthcare professionals to explore outsourcing for the latest treatments.

Key Market Challenges

Quality Control and Standardization

The drug discovery process for cancer immunotherapies is complex and continually evolving. Ensuring consistent quality and standards across different stages of this process, from target identification to clinical trials, is a significant challenge. Outsourcing projects often involve multiple sites, including research organizations, pharmaceutical companies, and contract research organizations (CROs). Coordinating and maintaining quality standards across these different entities can be challenging. Immunotherapy research and development employ a wide range of technologies and techniques, from genomics to cell-based assays. Standardizing procedures and ensuring quality across these diverse methods is essential. Quality control extends to data management and integration. Diverse data sources, such as genomics data, clinical trial data, and patient records, need to be standardized and integrated for comprehensive analysis.

Key Market Trends

Increasing Research in Checkpoint Inhibitors

Checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have demonstrated substantial clinical success in the treatment of various cancers, including melanoma, lung cancer, and more. This success has driven increased research and development in this area. Research is ongoing to explore the use of checkpoint inhibitors for a broader range of cancer types and stages. This expansion of indications requires extensive outsourcing services for clinical trial management and patient recruitment. Researchers are investigating combinations of checkpoint inhibitors with other immunotherapies, chemotherapy, targeted therapies, and radiation therapy. This approach requires extensive research and outsourcing support. Identifying predictive and prognostic biomarkers to guide the use of checkpoint inhibitors is a key focus of research. Outsourcing services play a critical role in biomarker discovery. The trend toward personalized medicine in cancer treatment emphasizes the need to identify which patients are most likely to benefit from checkpoint inhibitors. Outsourcing services contribute to this patient-centric approach.

Key Market Players

• Covance, Inc.
• Horizon Discovery Group PLC
• Crown Bioscience, Inc.
• Promega Corporation
• HD Biosciences Co., Ltd.
• BPS Bioscience, Inc.
• Genscript Biotech Corporation
• DiscoverX Corporation
• Celentyx Ltd.
• ImmunXperts SA

Report Scope:

In this report, the Global Cancer Immunotherapy Drug Discovery Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Service Type:

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Drug Type:

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• others

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Cancer Type:

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Others

Cancer Immunotherapy Drug Discovery Outsourcing Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market.

Available Customizations:

Global Cancer Immunotherapy Drug Discovery Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, others)
  • 5.2.2. By Service Type (Target Identification and Validation, Lead Screening and Characterization, Cell-based Assays)
  • 5.2.3. By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Service Type
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Service Type
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. India Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Service Type
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Australia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Service Type
      • 6.3.3.2.3. By Cancer Type
  • 6.3.4. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Service Type
      • 6.3.4.2.3. By Cancer Type
  • 6.3.5. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Service Type
      • 6.3.5.2.3. By Cancer Type

7. Europe Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Service Type
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Service Type
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. Germany Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Service Type
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. Spain Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Service Type
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Service Type
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. United Kingdom Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Service Type
      • 7.3.5.2.3. By Cancer Type

8. North America Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Service Type
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Service Type
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. Mexico Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Service Type
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Service Type
      • 8.3.3.2.3. By Cancer Type

9. South America Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Service Type
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Service Type
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. Argentina Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Service Type
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. Colombia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Service Type
      • 9.3.3.2.3. By Cancer Type

10. Middle East and Africa Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Service Type
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Service Type
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Saudi Arabia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Service Type
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. UAE Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Service Type
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Cancer Immunotherapy Drug Discovery Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Covance, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Horizon Discovery Group PLC
• 16.3. Crown Bioscience, Inc.
• 16.4. Promega Corporation
• 16.5. HD Biosciences Co., Ltd.
• 16.6. BPS Bioscience, Inc.
• 16.7. Genscript Biotech Corporation
• 16.8. DiscoverX Corporation
• 16.9. Celentyx Ltd.
• 16.10. ImmunXperts SA

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료